- Home
- CEE vs AVTX Comparison
CEE vs AVTX Comparison
Compare CEE & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- AVTX
- Stock Information
- Founded
- CEE 1990
- AVTX 2011
- Country
- CEE Germany
- AVTX United States
- Employees
- CEE N/A
- AVTX N/A
- Industry
- CEE Finance Companies
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CEE Finance
- AVTX Health Care
- Exchange
- CEE Nasdaq
- AVTX Nasdaq
- Market Cap
- CEE 79.2M
- AVTX 90.9M
- IPO Year
- CEE N/A
- AVTX 2015
- Fundamental
- Price
- CEE $11.97
- AVTX $8.91
- Analyst Decision
- CEE
- AVTX Strong Buy
- Analyst Count
- CEE 0
- AVTX 4
- Target Price
- CEE N/A
- AVTX $33.00
- AVG Volume (30 Days)
- CEE 22.0K
- AVTX 139.6K
- Earning Date
- CEE 01-01-0001
- AVTX 11-07-2024
- Dividend Yield
- CEE 3.86%
- AVTX N/A
- EPS Growth
- CEE N/A
- AVTX N/A
- EPS
- CEE N/A
- AVTX N/A
- Revenue
- CEE N/A
- AVTX $820,000.00
- Revenue This Year
- CEE N/A
- AVTX N/A
- Revenue Next Year
- CEE N/A
- AVTX N/A
- P/E Ratio
- CEE N/A
- AVTX N/A
- Revenue Growth
- CEE N/A
- AVTX N/A
- 52 Week Low
- CEE $7.80
- AVTX $3.95
- 52 Week High
- CEE $10.32
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- CEE 53.41
- AVTX 34.34
- Support Level
- CEE $11.16
- AVTX $9.00
- Resistance Level
- CEE $12.26
- AVTX $9.99
- Average True Range (ATR)
- CEE 0.44
- AVTX 0.84
- MACD
- CEE -0.07
- AVTX -0.02
- Stochastic Oscillator
- CEE 60.45
- AVTX 5.79
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).